SEC Form 4 · accession 0001437749-18-017794
INNOVUS PHARMACEUTICALS, INC. · INNV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dean Nuhaily
Director
Period of report
Oct 1, 2018
Accepted (ET)
Oct 2, 2018 · 4:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411879
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Oct 1, 2018 | A | 50,000 | A | Oct 1, 2018 | Oct 1, 2028 | Common Stock | 50,000 | 366,094 | D |
Explanation of responses
- F1Each restricted stock unit represents the contingent right to receive, at settlement, one share of common stock.
- F2The Reporting Person was granted a Restricted Stock Unit on October 1, 2018 of 50,000 shares, which were fully vested on the date of the grant. The RSU is for the Reporting Person's quarterly compensation as a member of the Board of Directors for the third quarter of 2018 and was valued on September 30, 2018 in accordance with the approved compensation plan for the non-employee members of the Board of Directors.
- F3These restricted stock units were granted pursuant to the Issuer's Amended and Restated 2016 Equity Incentive Plan.